The drug that started the GLP-1 weight loss category. The first GLP-1 receptor agonist approved specifically for chronic weight management. Largely superseded by semaglutide and tirzepatide, but still has a place for the right patient.
A daily GLP-1 injection that proved weight loss drugs could work, then got outperformed by its successors.Saxenda was groundbreaking in 2014. Before it, the GLP-1 drug class was used for diabetes. Saxenda was the first GLP-1 to get a dedicated FDA approval for weight management. Then semaglutide showed up and changed the benchmark entirely.
Liraglutide, Saxenda's active ingredient, is a GLP-1 receptor agonist, the same drug class as semaglutide and tirzepatide, but an earlier generation molecule. It works by mimicking the GLP-1 hormone your gut releases after eating, which signals the brain to reduce appetite and slows digestion. At 3 mg/day (the weight loss dose), it's meaningfully more potent than Victoza, which tops out at 1.8 mg/day for diabetes.
The practical limitation is that liraglutide has a short half life of about 13 hours, which is why you have to inject it every single day instead of once a week like Wegovy or Zepbound. That daily needle burden, combined with more modest weight loss numbers (about 8% versus 15-21% for the newer agents), has pushed Saxenda to a niche role. It's still a real medication that produces real results for some patients. But you should go in with accurate expectations.
Same GLP-1 mechanism as Wegovy, but older molecule, daily dosing, and lower ceiling on weight loss.Saxenda uses the same GLP-1 receptor mechanism as the newer drugs. The difference is in the molecule itself: liraglutide doesn't bind as persistently, needs to be taken daily, and ultimately doesn't suppress appetite as effectively at its maximum dose.
Liraglutide binds to GLP-1 receptors in the brain's hypothalamus and in the gut, sending fullness signals even when you haven't eaten much. This reduces total caloric intake over the course of the day. The effect is real, just less pronounced than with semaglutide or tirzepatide at comparable time points.
Like all GLP-1 drugs, liraglutide slows the rate at which food moves from the stomach into the small intestine. You stay full longer after meals. This is one of the main mechanisms driving reduced calorie intake, and it works reliably even with the older liraglutide molecule.
Saxenda starts at 0.6 mg daily and increases by 0.6 mg each week until you reach the target dose of 3 mg/day. That five week ramp reaches the full 3 mg dose by week five. You're not at a fully therapeutic dose until then, so don't judge results too early.
The SCALE trial ran for 56 weeks and enrolled over 3,700 participants. Average weight loss was 8%.The SCALE trial program was the registration study for Saxenda: over 3,700 patients with obesity or overweight followed for 56 weeks. The results were strong enough to earn FDA approval in 2014, though they look more modest compared to the semaglutide and tirzepatide data that came later.
"I still prescribe Saxenda in specific situations. If a patient is on a plan that covers it and not the newer ones, it's a real option, especially for someone who needs a more gradual start and is nervous about injectable medications. But I'm not going to tell a patient that 8% weight loss is equivalent to what they'd get from Wegovy. It's not. The data are clear. Saxenda opened the door; semaglutide walked through it."
Dr. Humberto Fernandez Miro, MD
Family Medicine
A legitimate option in specific situations. Not the first choice if you can access the newer agents.Saxenda has a narrower role than it did in 2016, but it isn't obsolete. There are clear situations where it makes sense and clear situations where you'd be leaving results on the table.
⚕️Always consult your doctor before starting any weight loss medication.
GI side effects are frequent and tend to be more persistent than with semaglutide. Daily injections also mean more injection site reactions.Saxenda has a notable GI side effect burden, with higher rates than Wegovy in absolute terms, and with the added complication that daily dosing means daily injection site reactions for some patients. The nausea in particular can be more persistent than with the once weekly agents.
Saxenda has a high list price and less consistent insurance coverage than the newer agents.Saxenda's list price is actually higher than Wegovy's, which surprises many patients. And despite being on the market for over a decade, insurance coverage can be patchier than you'd expect, since many plans have migrated their preferred formulary to semaglutide and tirzepatide.
Saxenda vs. the other leading weight loss medications.How does Saxenda stack up against the other leading weight loss medications?
| Medication | Avg. Weight Loss | Form | Food Restriction | Approved For |
|---|---|---|---|---|
| 💉Saxenda You're here | 8% | Daily Injection | None ✓ | Weight Loss |
| 💉Wegovy | 15% | Weekly Injection | None ✓ | Weight Loss |
| 💉Zepbound | 21% | Weekly Injection | None ✓ | Weight Loss |
| 💊Foundayo | 9-15% | Daily Pill | None ✓ | Weight Loss |